Evidence map›Paper›PMID 35226381›Full record

ArticleThe Prostate2022

Fresh tissue procurement and preparation for multicompartment and multimodal analysis of the prostate tumor microenvironment.

Ross A Vitek, Wei Huang, Peter G Geiger, Erika Heninger, Joshua M Lang, David F Jarrard, David J Beebe, Brian P Johnson

Open access · bronzeAbstract read
In one paragraph

Article in The Prostate, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Ross A VitekDepartment of Pathology and Laboratory Medicine, University of Wisconsin, Madison, Wisconsin, USA.ORCID 0000-0002-7148-7202
Wei HuangDepartment of Pathology and Laboratory Medicine, University of Wisconsin, Madison, Wisconsin, USA.ORCID 0000-0003-0813-4188
Peter G GeigerDepartment of Pathology and Laboratory Medicine, University of Wisconsin, Madison, Wisconsin, USA.
Erika HeningerCarbone Cancer Center, University of Wisconsin, Madison, Wisconsin, USA.ORCID 0000-0003-0166-9972
Joshua M LangCarbone Cancer Center, University of Wisconsin, Madison, Wisconsin, USA.ORCID 0000-0002-0943-8872
David F JarrardDepartment of Urology, University of Wisconsin, Madison, Wisconsin, USA.ORCID 0000-0001-8444-7165
David J BeebeDepartment of Pathology and Laboratory Medicine, University of Wisconsin, Madison, Wisconsin, USA.ORCID 0000-0002-0415-9006
Brian P JohnsonDepartment of Pathology and Laboratory Medicine, University of Wisconsin, Madison, Wisconsin, USA.ORCID 0000-0001-8163-4731
University of Wisconsin–Madison · USUniversity of Wisconsin System · US

Funding

UW COMPREHENSIVE CANCER CENTER SUPPORTP30CA014520 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Christian Capitini · 1985 to 2026
$142.6M
Molecular and Cellular Mechanisms of Tumor DevelopmentT32CA157322 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI ALEXANDER, CAROLINE M · 2011 to 2017
$1.6M
Elucidating AHR signaling interplay in orofacial clefting and endocrine disruption using microplate microfluidicsR00ES028744 · NIEHS · MICHIGAN STATE UNIVERSITY · PI JOHNSON, BRIAN P. · 2020 to 2022
$745k
Special BD LSR FortessaS10OD018202 · OD · UNIVERSITY OF WISCONSIN-MADISON · PI PATANKAR, MANISH S · 2014 to 2014
$351k
Elucidating AHR signaling interplay in orofacial clefting and endocrine disruption using microplate microfluidicsK99ES028744 · NIEHS · UNIVERSITY OF WISCONSIN-MADISON · PI JOHNSON, BRIAN P. · 2018 to 2019
$200k
NCI NIH HHS P30 CA014520NCI NIH HHS T32 CA157322NIEHS NIH HHS K99 ES028744NIEHS NIH HHS R00 ES028744NIH HHS S10 OD018202
6 · The paper itself

Abstract

backgroundProstatic cancers include a diverse microenvironment of tumor cells, cancer-associated fibroblasts, and immune components. This tumor microenvironment (TME) is a known driving force of tumor survival after treatment, but the standard-of-care tissue freezing or fixation in pathology practice limit the use of available approaches/tools to study the TME's functionality in tumor resistance. Thus, there is a need for approaches that satisfy both clinical and laboratory endpoints for TME study. Here we present methods for clinical case identification, tissue processing, and analytical workflow that are compatible with standard histopathology while enabling molecular and functional interrogation of prostate TME components.

methodsWe first performed a small retrospective review to identify cases where submission of alternate prostate tissue slices and a parallel live tissue processing protocol complement traditional histopathology and enable viable multicompartment analysis of the TME. Then, we tested its compatibility with commonly employed methods to study the microenvironment including quantification of components both in situ and after tissue dissociation. We also evaluated tissue digestion conditions and cell isolation techniques to aid various molecular and functional endpoints.

resultsWe identified Gleason Grade Group 3+ clinical cases where tumor volume was sufficient to allow slicing of unfixed tissue and distribution of alternating tissue slices to standard-of-care histopathology and viable multi-modal TME analyses. No single method was found that preserved cellular sub-types for all downstream readouts; instead, tissues were further divided so techniques could be catered to each endpoint. For instance, we show that incorporating the protease dispase into tissue dissociation improves viability for culture and functional analyses but hinders immune cell analysis by flow cytometry. We also found that flow activated cell sorting provides highly pure cell populations for quantitative reverse-transcription polymerase chain reaction and RNA-seq while isolation using antibody-labeled paramagnetic particles facilitated functional coculture experiments.

conclusionsThe identification of candidate cases and use of these techniques enable translational research and the development of molecular and functional assays to facilitate prostate TME study without compromising standard-of-care histopathological diagnosis. This allows bridging clinical histopathology and further interrogation of the prostate TME and promises to advance our understanding of tumor biology and unveil new predictive and prognostic markers of prostate cancer progression.

Indexed as

Cancer-Associated FibroblastsProstatic NeoplasmsTissue and Organ ProcurementHumansMaleProstateTumor Microenvironmentfunctional analysesmolecular analysesprostatetissue processingtumor microenvironment

Identifiers

PMID35226381
PMCPMC9010374
OpenAlexW4214679312

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.